Filing Flows

Filing Flows › 8-K events › Anavex Life Sciences

Anavex Life Sciences: departure or appointment of directors and officers

Form 8-K filed Nov 3, 2026 · items 5.02

CEO changesAnavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors

What the filing says

On November 1, 2026, the Board of Directors (“Board”) of Anavex Life Sciences Corp. (“Anavex” or the “Company”), appointed Terrie Kellmeyer, Ph.D. as the Company’s Chief Executive Officer (“CEO”) and President effective immediately. Kellmeyer, age 59, has served as the Company’s Interim CEO since May 4, 2026.

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.